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Abstract
In severe hemorrhagic shock, left ventricular (LV) diastol-
ic dysfunction is an early sign of cardiac failure due to
compromised myocardial oxygenation. Immediate fluid
replacement or, in particular, administration of a hemo-
globin-based oxygen carrier (diaspirin cross-linked he-
moglobin; DCLHb) improves myocardial oxygenation;
therefore, positive effects on LV diastolic function could
be expected. The effects of fluid resuscitation from se-
vere hemorrhagic shock with DCLHb were investigated
in 20 anesthetized domestic pigs. After generation of a
critical left anterior descending coronary artery stenosis
(narrowing of the artery until disappearance of reactive
hyperemia after a 10-second complete vessel occlusion),
hemorrhagic shock (mean arterial blood pressure 45 mm
Hg) was induced within 15 min by controlled blood with-
drawal and maintained for 60 min. Fluid resuscitation
consisted of replacement of the plasma volume with-
drawn during hemorrhage by infusion of either 10%
DCLHb (DCLHb group, n = 10) or 8% human serum albu-
min (HSA) oncotically matched to DCLHb (HSA group,
n = 10). After completion of resuscitation, an observation
period of 60 min elapsed. Measurements of central
hemodynamics, myocardial oxygenation, and LV dia-
stolic function were performed at baseline, after induc-
tion of critical coronary artery stenosis, after 60 min of
hemorrhagic shock, immediately after resuscitation, and
60 min later. While 5 out of 10 animals treated with HSA
died within the first 20 min after fluid resuscitation from
acute LV pump failure, all DCLHb-treated animals sur-
vived until the end of the protocol (p ! 0.05). Despite
superior myocardial oxygenation due to augmentation
of the arterial O2 content as well as of coronary perfusion
pressure, no beneficial effects on LV diastolic function
were observed after infusion of DCLHb. Peak velocity of
LV pressure decrease (dp/dtmin) did not reveal significant
differences between the two groups. Immediately after
completion of fluid resuscitation with DCLHb, the time
constant of LV diastolic relaxation (Ù) was prolonged
when compared with HSA-treated animals (p ! 0.05),
indicating retardation of early LV diastolic relaxation.
Our data suggest that DCLHb fails to improve LV diastol-
ic function after fluid resuscitation from severe hemor-
rhagic shock. However, positive effects on myocardial
perfusion and oxygenation result in a significant reduc-
tion of the mortality of severe hemorrhagic shock.
Copyright © 2001 S. Karger AG, Basel
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Introduction
Adequate cardiac performance is crucial for the out-
come after fluid resuscitation from severe hemorrhagic
shock, since heart failure induced by dilutional anemia
may become the life-limiting complication in this situa-
tion [1, 2]. An early marker of left ventricular (LV) dys-
function despite augmented systolic contractility is the
alteration of LV diastolic properties during shock [3].
The LV diastolic function strictly depends on an ade-
quate oxygenation of the myocardium [4]. During shock,
the latter is jeopardized by a significant reduction of the
coronary perfusion pressure (CPP) and thus myocardial
perfusion.
Since primary therapy of hemorrhagic shock is usually
performed with acellular, i.e., crystalloidal and colloidal
solutions, the arterial O2 content falls due to the dilution
of the remaining red blood cell (RBC) mass. Depending
on the degree of dilution, myocardial oxygenation may
become critical, a reason why fluid resuscitation with cell-
free solutions was found ineffective in restoration of myo-
cardial O2 supply [5, 6]. Reduction of myocardial O2 sup-
ply enhances myocardial stiffness [4] as an early sign of
LV diastolic dysfunction.
Actually, the ‘state-of-the art’ therapy to overcome the
reduced myocardial O2 supply is the transfusion of
packed RBC. An alternative to this RBC transfusion
might be the immediate infusion of a hemoglobin-based
artificial oxygen carrier (HBOC) [7, 8]. HOBCs are hype-
roncotic solutions acting like ‘plasma expanders’ with the
ability to transport O2 [9]. Therefore, most of the HBOCs
seem to be suitable for the initial treatment of hemorrhag-
ic shock. Moreover, most of the HBOCs possess specific
vasoconstrictive properties, mainly induced by scaveng-
ing of the endogeneic vasodilator nitric oxide [10, 11].
In the present experimental animal model, the effects
on LV diastolic function were investigated after infusion
of 10% diaspirin cross-linked hemoglobin (DCLHb) and
compared to an equioncotic human serum albumin
(HSA) solution. In all animals the LV performance was
initially compromised by a critical stenosis of the left
anterior descending artery (LAD) [12]. With respect to the
vasoconstrictive and O2 transport properties of DCLHb,
we assumed positive effects on the LV diastolic function,
leading to the hypothesis that fluid resuscitation from
hemorrhagic shock with DCLHb would (1) improve LV
diastolic function and (2) prove superior to HSA void of
O2-transporting and vasoconstrictive properties.
Materials and Methods
The experiments were performed as part of a comprehensive
experimental program; parts of the data have been published already
[see 6]. The experimental protocol has been described in detail; there-
fore, in the following, we concentrate on the methodology exerted for
analysis of the diastolic function.
Anesthesia and Animal Preparation
20 healthy farm-bred pigs of either sex (body weight 26.2 B
4.2 kg) were anesthetized by intramuscular injection of 10 mg/kg
ketamine, 1 mg/kg midazolam, and 0.03 mg/kg atropine, followed by
intravenous injection of 1.5 mg/kg methohexital, 0.03 mg/kg fenta-
nyl, and 0.2 mg/kg pancuronium and by continuous intravenous
infusion of midazolam (0.02 mg/kg/min), fentanyl (0.8 Ìg/kg/min),
and pancuronium (4 mg/h; for trade names of applied anesthetics cf.
appendix). Ventilation with FiO2 = 0.5 was adjusted to maintain
arterial normocapnia. The animals were instrumented with two tip
manometer catheters (PC 370; Millar Instruments, Houston, Tex.,
USA) placed into the abdominal aorta and into the chamber of the
left ventricle, respectively, and a Swan-Ganz catheter (right ventricu-
lar ejection fraction/volumetric catheter; Baxter, Irvine, Calif., USA)
floated into the pulmonary artery. After midline sternotomy, the
pericardium was opened, the LAD dissected free from the surround-
ing tissue, and two Teflon-coated copper-wires were wound around
the LAD for induction of critical coronary stenosis. Two pairs of pie-
zoelectronic ultrasonic transducers (5 MHz, diameter 1.5 mm; Dr.
W. Heimisch, Deutsches Herzzentrum, Munich, Germany) were
inserted into the subendocardial layer of the LV myocardium, one
pair being located in the anterior and one in the posterior wall.
Experimental Protocol
After termination of surgical preparation and placement of the
different measuring devices, a 15-min stabilization period was
allowed to elapse, and the first set of measurements (‘baseline’) was
performed. According to the definition of Gould et al. [13], a critical
coronary stenosis (tightening the LAD until loss of reactive hyperem-
ia after a 10-second complete vessel occlusion) was induced, followed
by the second measurement (‘critical stenosis’). Hemorrhagic shock
(mean aortic pressure, MAP, 45 mm Hg) was induced within 15 min
by controlled withdrawal of blood and maintained for 60 min by fur-
ther withdrawal or uptake of blood (third measurement: ‘60 min
shock’) [14]. Thereafter, the animals were resuscitated according to a
prospectively fixed randomization plan with either 10% DCLHb or
8% HSA (both provided by Baxter Healthcare, Deerfield, Ill., USA)
oncotically matched to DCLHb (infusion rate 2 ml/kg/min; table 1).
The infused volume of either solution was equivalent to the volume
of plasma withdrawn during induction of shock (16 B 3 ml DCHLb,
18 B 3 ml HSA). Immediately after completion of fluid resuscita-
tion, the fourth measurement (‘resuscitation’) was performed, fol-
lowed by an observation period of 60 min and the final measurement
(‘60 min resuscitation’). Finally, all animals were sacrificed by intra-
cardial injection of a saturated potassium chloride solution.
Parameters
Hemodynamics. Heart rate, MAP, LV pressure (LVP), LV end-
diastolic pressure (LVEDP), central venous pressure (CVP), and
mean pulmonary arterial pressure were determined with the devices
described above. The systemic vascular resistance was calculated and
indexed to body surface area (cf. appendix).
pH at 37 °C
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Fig. 1. Determination of the time constant of LV diastolic relaxation
(Ù) as the negative reciprocal of the asymptotic slope between LVP0
and LVPasympt.
Table 1.  Characteristics of the two resuscitation fluids investigated
Parameter 10% DCLHb 8% Albumin
7.4 7.41
Colloid osmotic pressure, mm Hg 42 43.8
Endotoxin activity, EU/ml ! 0.1 ! 0.06
Osmolality, mosm/kg 300 284
Sodium, mEq/l 140 132
Potassium, mEq/l 4.0 3.8
Calcium, mEq/l 2.3 1.6
Magnesium, mEq/l 1.0 0.7
Chloride, mEq/l 110 116
Lactate, mEq/l 32 36
Myocardial Oxygenation. Myocardial O2 delivery was calculated
as the product of regional myocardial blood flow and arterial O2 con-
tent. The CPP was calculated as the difference between diastolic aor-
tic pressure and LVEDP (cf. appendix). The myocardial perfusion
was assessed by the radioactive microsphere technique which has
already been described in detail elsewhere [6, 15, 16].
Arterial and coronary venous blood gases were determined with
an ABL 300 device (Radiometer, Copenhagen, Denmark). Concen-
tration and O2 saturation of hemoglobin were measured by absor-
bance spectrophotometry (682 CO oximeter; Instrumentation Labo-
ratory, Lexington, Mass., USA). After infusion of DCLHb, the hemo-
globin content in whole blood was the sum of erythrocytic, native
hemoglobin and DCLHb dissolved in plasma. Therefore, absorbance
was first analyzed in whole blood. Subsequently, blood samples were
centrifuged (160 g for 15 min), and the absorbance was determined
within the plasma (i.e., the concentration of DCLHb). The O2 satura-
tion kinetics of DCLHb were deduced from a specific O2-binding
curve supplied by Baxter Healthcare.
LV Diastolic Function. The global LV compliance was deduced
from the maximum rate of LV pressure decline (LVdp/dtmin). The
time constant of LV diastolic pressure decrease ‘Ù’ was determined as
published by Beattie et al. [17]. The monoexponential pressure-time
decay relationship is described as:
LVP(t) = [LVP0 –LVPasympt] WeAt + LVPasympt (1)
where A = negative reciprocal of Ù (Ù = –1/A), LVP0 = LVP when t =
0, and LVPasympt = asymptotic LVP when t → ∞ (fig. 1). Mathemati-
cal transformation yields:
dp(t)/dt = A WLVP(t)–a WLVPasympt (2)
When LVdp/dt is plotted against LVP, linear least-square regres-
sion between LVdp/dtmin and LVdp/dt = 0 yields a slope of –1/Ù in
milliseconds and the intersection with the abscissa coinciding with
LVPasmypt.
The regional function of the normally perfused and poststenotic
myocardium was assessed by sonomicrometric measurement of myo-
cardial segment lengths defined by the distance between the piezo-
electronic crystals at end systole and end diastole. End systole was
defined as the maximal slope of LVP (i.e., LVdp/dtmax), end diastole
as the onset of LV isovolumetric contraction.
Statistics
Statistical analysis was performed using the SAS 6.12 software
package (SAS Institute, Cary, N.C., USA). The distribution of data
was tested by the Shapiro-Wilks test. Normally distributed data were
analyzed by ANOVA. Significant ‘within-group’ differences over
time detected by ANOVA were further analyzed with a post hoc Stu-
dent-Newman-Keuls test. Significant ‘between-group’ differences
were further analyzed with a Student t test. Normally distributed
parameters are depicted as mean B SD. When the data were not
normally distributed, an ANOVA on ranks (rANOVA) was per-
formed. Post hoc analysis of differences revealed by rANOVA was
performed with a Wilcoxon signed-rank test. These results are
depicted as median B semi-interquartile range. The alpha error was
set at 5% for either test.
Results
Parts of the results of this extensive study have already
been published [6, 16]. Briefly, it was demonstrated that
all animals treated with DCLHb survived the observation
period after completion of fluid resuscitation, whereas 5
out of 10 HSA-treated animals died of acute LV failure
within 20 min after termination of resuscitation. This
finding was explained by superior myocardial oxygena-
tion after infusion of DCLHb, resulting from augmenta-
tion of CaO2 as well as from restoration of CPP, leading to
complete reversal of shock-induced subendocardial isch-
emia and to improvement of shock-induced disturbances
of the distribution of regional myocardial perfusion.
Moreover, it could be shown that 60 min after resuscita-
tion, 33% of the O2 consumed by the poststenotic myocar-
dium was delivered by DCLHb.
Heart rate, min–1
LVP, mm Hg
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Table 2. Hemodynamics and arterial O2-content
Parameter Group Baseline Critical
coronary stenosis
60 min
shock
Resuscitation 60 min
resuscitation
DCLHb
HSA
123B20
116B14
127B17
118B15
181B22*
181B24*
147B14*, #
155B15*, #
138B20
149B16#
MAP, mm Hg DCLHb
HSA
117B20
114B20
124B18
117B15
45B2*
46B4*
113B13*, §
66B16*, #
115B30§
69B16#
SVRI,
dyn Ws W cm–5 W m–2
DCLHb
HSA
2,273B627
1,848B505
2,430B657
1,930B348
2,535B785
2,136B656
2,271B450§
866B166*, #
2,650B833§
831B169#
CaO2, ml Wdl–1 DCLHb
HSA
13.2B1.7
12.7B1.2
12.7B2.0
12.7B1.5
11.6B1.3
11.6B1.9
10.3B0.9*, #, §
6.8B1.0*, #
9.3B1.2#, §
6.6B0.3#
Results and differences between DCLHb and HSA at the different measurement time points.
MAP = Mean arterial pressure; SVRI = systemic vascular resistance indexed to body surface area; CaO2 = arterial oxygen content [6].
* p ! 0.05 vs. previous measurement; # p ! 0.05 vs. baseline; § p ! 0.05 DCLHb vs. HSA.
Table 3. LV diastolic function
Parameter Group Baseline Critical
coronary stenosis
60 min
shock
Resuscitation 60 min
resuscitation
DCLHb
HSA
134B19
138B26
137B21
136B16
68B11*
74B15*
120B26§, *
91B29
125B47
88B19#
LVEDP, mm Hg DCLHb
HSA
6B2
8B3
6B2
8B3
3B3*
4B2*
9B3*
17B8*, #, §
9B4
18B9#, §
LVdp/dtmin,
mm Hg Ws–1
DCLHb
HSA
–2,364B497
–2,239B483
–2,229B552
–2,261B418
–1,097B368*
–1,047B333*
–1,683B658*
–1,435B484#
–1,753B704
–1,337B248#
Ù, ms DCLHb
HSA
28.8B7.9
27.8B4.3
29.7B6.9
27.1B6.9
20.9B10.5
25.3B7.2
33.6B9.9*, §
22.9B5.4
30.8B8.2
24.3B3.6
EDSLcontrol, mm DCLHb
HSA
11.9B2.5
11.9B2.7
11.8B2.6
12.1B3.1
10.7B2.5
10.3B2.4
12.2B2.7
12.1B3.3
11.9B2.7
12.2B4.3
EDSLpoststen, mm DCLHb
HSA
13.3B3.5
11.5B2.6
13.3B3.4
11.3B2.6
12.2B3.4
9.8B2.5
13.3B3.9
11.9B2.9
13.4B3.6
11.9B3.9
Results and differences between DCLHb and HSA at the different measurement time points.
LVP = Left ventricular pressure; LVEDP = left ventricular end-diastolic pressure;
LVdp/dtmin = maximum rate of left ventricular pressure decline; Ù = time constant of diastolic relaxation;
EDSLcontrol and EDSLpoststen = end-diastolic myocardial segment length in normally perfused and poststenotic myocardium.
* p ! 0.05 vs. previous measurement; # p ! 0.05 vs. baseline; § p ! 0.05 DCLHb vs. HSA.
Critical Coronary Stenosis
Induction of critical LAD stenosis did not produce
changes in the investigated parameters of LV diastolic
properties within each animal. Neither at ‘baseline’ nor at
‘critical coronary stenosis’ were any significant differ-
ences between the groups established (table 2).
Hemorrhagic Shock
At ‘60 min shock’, no differences between the groups
were observed concerning the investigated parameters of
LV diastolic function (table 3). LVP and LVEDP de-
creased by 49 and 50%, respectively (p ! 0.05), while the
time constant of LV diastolic relaxation ‘Ù’ as well as the
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Fig. 2. Immediately after fluid resuscitation, the time constant of LV
diastolic relaxation (Ù) was prolonged in DCLHb-treated animals.
60 min after resuscitation, no significant differences between
DCLHb group and HSA-survivors were observed. § p ! 0.05 DCLHb
vs. HSA; * p ! 0.05 vs. previous measurement.
end-diastolic segment length did not reveal significant
alterations in the normally perfused or in the poststenotic
myocardium. Maximal LV pressure decline (LVdp/dtmin)
decreased by 52% (p ! 0.05).
Resuscitation
The MAP was increased by both resuscitation modes,
but MAP rose more pronounced in the DCLHb-group
(p ! 0.05). Consistently, the systemic vascular resistance
indexed to body surface area was significantly higher in
DCLHb-treated animals immediately as well as 60 min
after resuscitation.
The infusion of DCLHb enabled a permanent restora-
tion of LVP and LVEDP (p ! 0.05), while in HSA-treated
animals the LVEDP was elevated immediately after re-
suscitation when compared with ‘baseline’ (p ! 0.05).
60 min after resuscitation, even HSA survivors presented
a significantly higher LVEDP than DCLHb-treated ani-
mals.
The end-diastolic myocardial segment length was not
influenced in normally perfused or in poststenotic myo-
cardia by either of the two treatments. LVdp/dtmin did not
show significant differences between the groups, but in
contrast to HSA survivors, LVdp/dtmin was only restored
to baseline values by infusion of DCLHb.
In contrast to LVdp/dtmin, Ù was elevated after infusion
of DCLHb with significantly higher values compared
with ‘baseline’ as well as with HSA-treated animals. How-
ever, this difference vanished during the subsequent ob-
servation period, so that 60 min after resuscitation no dif-
ferences to the 5 HSA survivors were observed (fig. 2, 3).
Discussion
The main finding of the study was the reduction of
mortality from 50% within the HSA-treated control group
to 0% after resuscitation with the HBOC. The crucial
advantage of DCLHb compared with HSA was the supe-
rior myocardial oxygenation due to the augmentation of
arterial O2 content and of CPP enabling a complete rever-
sal of shock-induced subendocardial ischemia [6].
Therefore, we hypothesized the presence of significant
differences between groups concerning the LV diastolic
function which in turn is a sensitive marker of myocardial
ischemia. However, the investigated parameters reflect-
ing LV diastolic properties did not demonstrate superiori-
ty of the HBOC. Although only treatment with DCLHb
restored LVdp/dtmin to baseline values, neither LVdp/
dtmin nor end-diastolic myocardial segment length re-
vealed significant differences between the DCLHb group
and the 5 HSA survivors. Converse to our hypothesis, the
time constant of LV diastolic relaxation ‘Ù’ was elevated
over the baseline level immediately upon infusion of
DCLHb, indicating retardation of LV isovolumic relax-
ation.
At RBC-free fluid resuscitation from hemorrhagic
shock, the heart is responsible for an adequate compensa-
tory hemodynamic response to hemodilution, while at the
same time the cardiac function is endangered due to an
imbalance between increased myocardial O2 demand and
reduced O2 supply. As a consequence, acute myocardial
failure becomes apparent [18]. The imbalance of myocar-
dial oxygenation is aggravated when the myocardial blood
flow a priori is compromised due to coronary stenosis. A
critical stenosis (F75–85%) does not affect blood flow at
rest, but completely deprives the vessel of its vasodilator
Fig. 3. Typical LV pressure/work diagrams of 1 DCLHb-treated ani-
mal (left) and 1 HSA survivor (right). Immediately after resuscita-
tion, the asymptotic slope is right shifted in the DCLHb-treated ani-
mal, indicating prolongation of the LV diastolic relaxation time con-
stant (Ù). 60 min after resuscitation, this difference has disappeared.
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reserve [19]. Hence, the compensatory increase of coro-
nary blood flow during hemodilution cannot take place
[12]. Thereby myocardial oxygenation and energy metab-
olism get impaired which directly affects isovolumic LV
relaxation: as the transport of ionized calcium, which is
released from its binding site on troponin C in order to
allow the actin-myosin cross-bridges to dissociate, occurs
against a large concentration gradient, high-energy phos-
phates are required for active myocardial relaxation [20,
21]. Thus, myocardial ‘stiffness’ and compromised LV
diastolic function, as revealed by prolongation of ‘Ù’, are
accepted to be consequences of insufficient myocardial
oxygenation [4].
Although LV afterload was increased after infusion of
DCLHb due to peripheral vasoconstriction, the myocar-
dial oxygenation remained adequate [6]. Therefore, the
question arises how the improved myocardial oxygena-
tion fits with deteriorated LV diastolic function upon
DCLHb infusion. Retardation of LV isovolumic relax-
ation, as shown by the prolongation of Ù immediately
upon infusion of DCLHb, is all the more remarkable, as
even a period of 1 h of hemorrhagic shock in the presence
of a critical coronary stenosis did not exert any significant
changes of Ù.
If prolongation of Ù indeed reflects inadequate myocar-
dial oxygenation, it may be speculated that O2 transported
by DCLHb was not be delivered to the myocardium due
to either insufficient molecular O2 release or impairment
of the myocardial perfusion as a result of coronary vaso-
constriction.
However, our data demonstrate that 33% of the O2
consumed by the poststenotic myocardium was supplied
by DCLHb [6] and that it is unlikely that the O2 transport
is less effective to the myocardium with uncompromised
perfusion. Moreover, the O2 affinity of DCLHb is lower
when compared to native hemoglobin. The P50 value of
DCLHb is higher, and the O2 dissociation curve is slightly
shifted to the right as compared with native hemoglobin.
This should allow DCLHb to release O2 more readily to
the tissues [22].
In a previous study [23], we could demonstrate a direct
vasoconstrictive effect of DCLHb on coronary and intra-
myocardial vessels, as the coronary vascular resistance
was elevated after intended hemodilution with DCLHb.
DCLHb-induced vasoconstriction might affect myocar-
dial perfusion, leading to redistribution of myocardial
blood flow, increased myocardial blood flow heterogene-
ity, and regional myocardial hypoperfusion. However, in
the experimental model of the present study, we could
also demonstrate that resuscitation from hemorrhagic
shock with DCLHb tended to restore the normal distribu-
tion of regional myocardial blood flow [16].
There is no proof of inadequate myocardial oxygena-
tion after infusion of DCLHb, but probably the alteration
of ‘Ù’ upon hemodilution with DCLHb is caused by
changes of macrohemodynamic parameters: normally,
hemodilution increases LV preload by augmentation of
venous return and decreases LV afterload due to periph-
eral vasodilation. The diastolic function has been shown
to remain unchanged during moderate acute isovolemic
hemodilution (hematocrit 20%) [24]. Besides, hemodilu-
tion with DCLHb seems to have contrary effects, as vaso-
constriction after administration of DCLHb has been
demonstrated to be more strongly pronounced in arteries
than in veins [25]. Thereby, LV preload is reduced due to
sequestration of the circulating blood volume in capaci-
tance blood vessels, whereas LV afterload is increased due
to nitric oxide scavenging.
Alterations of LV pre- and afterload (e.g., by adminis-
tration of vasodilating and vasoconstrictive agents) have
been shown to elicit shifts in the diastolic pressure-vol-
ume relation which has been explained by the influence of
the pericardial pressure [26]. However, the pericardium
was kept open throughout the whole protocol. Therefore,
the end-diastolic myocardial segment length (EDSLcontrol
and EDSLpoststen), reflecting the LV end-diastolic volume,
might be a parameter unsuitable for assessment of LV dia-
stolic properties in this experimental setting.
Despite the open pericardium, the transmural LVP
was significantly elevated by the increased afterload fol-
lowing infusion of DCLHb. Nevertheless, the peak veloci-
ty of the LVP decrease (LVdp/dtmin) did not indicate
alterations of LV diastolic function. Yet, the LVdp/dtmin
is highly dependent on LV pre- and afterload which were
significantly influenced by DCLHb. Due to load depen-
dence, the LVdp/dtmin might also be unreliable for the
evaluation of LV diastolic function in this situation [27].
In contrast, ‘Ù’ is a preload-independent measure of
isovolumic relaxation [28]. Variations of LV afterload do,
however, significantly correlate with alterations of the iso-
volumic relaxation time [29, 30].
Deterioration of the LV diastolic function immediate-
ly upon resuscitation with DCLHb seems to be predomi-
nantly the result of vasoconstriction. Therefore, our hy-
pothesis of a DCLHb-improved LV diastolic function
after resuscitation has to be rejected.
However, the positive effects of the vasoconstrictive
and O2-transporting properties of DCLHb on global myo-
cardial oxygenation enabled adequate myocardial O2 sup-
ply and thereby complete reversal of subendocardial isch-
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emia. Although DCLHb obviously failed to restore the
LV diastolic function, the beneficial effects on myocardial
oxygenation clearly predominate, resulting in a signifi-
cant reduction of the mortality [6].
Despite repeatedly proven superiority of DCLHb in
preclinical models, a clinical phase III study conducted at
18 US trauma centers indicated a significantly higher
mortality in DCLHb-treated patients. After an interim
data analysis, patient enrollment was suspended, as it
seemed unlikely to meet the expected end points for effi-
cacy and safety [31].
In September 1998, Baxter Healthcare terminated fur-
ther clinical investigation in DCLHb. Nevertheless, in-
vestigation and development of new HBOC for operative
and emergency medicine remains an issue of major inter-
est.
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Appendix
Calculations
The body surface area (BSA in m2) was calculated according to
Holt et al. [32]:
BSA = k WBW2/3 (m2) (3)
where BW = body weight (in kg) and k = 9.
The systemic vascular resistance index (SVRI) was calculated as:
SVRI = 
(MAP – CVP) W79.9
CI
 dyn Ws
cm5 Wm2
 (4)
The arterial oxygen content (CaO2) was calculated as:
CaO2 = ([Hbporcine] WSaO2porcine W1.34) +
([DCLHb] WSaO2DLCHb W1.39) + paO2 W0.0031 (5)
Anesthetics
For induction and maintenance of anesthesia, the following drugs
were applied: ketamine (Ketavet™; Parke-Davis, Berlin, Germany),
midazolam (Dormicum™; Roche, Grenzach, Germany), atropine
(Atropinsulfat™; Braun, Melsungen, Germany), methohexital (Bre-
vimytal™; Lilly, Bad Homburg, Germany), fentanyl (Fentanyl™;
Janssen, Neuss, Germany), and pancuronium (Pancuronium™; Cu-
ramed, Karlsruhe, Germany).
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